Suchergebnisse - "Campion, Nicholas J"

PubPharm (23)

1

Nasal IL-13 production identifies patients with late-phase allergic responses

enthalten in: The Journal of allergy and clinical immunology | 2023

von Campion, N. | Villazala-Merino, S. | Thwaites, R. | +19

2

Low free triiodothyronine and immune-related hyperthyroidism are associated with overall and progression-free survival in head and neck squamous cell carcinoma treated with pembrolizumab

enthalten in: International immunopharmacology | 2023

von Haas, M. | Lein, A. | Fuereder, T. | +7

3

The "real life" efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP

enthalten in: Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale | 2023

von Campion, N. | Brugger, J. | Tu, A. | +8

4

The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP

enthalten in: Journal of otolaryngology, head & neck surgery | 2023

von Campion, N. | Brugger, J. | Tu, A. | +8

5

The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP

enthalten in: Journal of otolaryngology, head & neck surgery | 2023

von Campion, N. | Brugger, J. | Tu, A. | +8

6

The nasal microbiome in patients suffering from non-steroidal anti-inflammatory drugs-exacerbated respiratory disease in absence of corticosteroids

enthalten in: Frontiers in immunology | 2023

von Bartosik, T. | Campion, N. | Freisl, K. | +8

7

Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro

enthalten in: Investigational new drugs | 2022

von Jank, B. | Lenz, T. | Haas, M. | +5

8

Chronic rhinosinusitis symptoms differentially impact the likelihood of major depressive disorders

enthalten in: Laryngoscope investigative otolaryngology | 2022

von Liu, D. | Bartosik, T. | Campion, N. | +8

9

Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro

enthalten in: Investigational new drugs | 2022

von Jank, B. | Lenz, T. | Haas, M. | +5

10

Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro

enthalten in: Investigational new drugs | 2022

von Jank, B. | Lenz, T. | Haas, M. | +5